GRAIL, Inc.
No SEC Form 4 filings for $GRAL in the last 30 days.
See all $GRAL insider activity →Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
GRAIL (GRAL) reported Q2 2026 results from its Galleri multi-cancer early detection test. The company cited PATHFINDER 2 (35,000 participants) and NHS-Galleri (140,000, three annual tests) presented at ASCO, with false positives under 0.5% and 61,000 tests sold in Q2. Q2 screening revenue was $42.6M, up 24% YoY; H1 revenue exceeded $80M. GRAIL completed a $110M financing with Samsung and is expanding internationally.
GRAIL said the FDA Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for Galleri, a multi-cancer early detection blood test. The submission cites PATHFINDER 2 (25,490 participants, one year) and NHS-Galleri (over 70,000). GRAIL says Galleri detects methylation patterns, with low false positives and accurate signal origin prediction.
Over the past 7 days, alphai's AI scored 2 news stories mentioning GRAL (GRAIL, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent GRAL coverage spans financial news, regulation and earnings.
The scheduled FDA panel review is a time-bound regulatory milestone that can increase volatility into the decision window.
Near-term trading focus is on FDA PMA progress and commercialization momentum (test volumes, partnerships, and international expansion).
The FDA advisory committee review is a key regulatory milestone that can reprice approval odds for Galleri and related cash-flow expectations.
The scheduled FDA advisory committee review is a near-term regulatory catalyst that can shift perceived approval odds and valuation risk for GRAL.
The filing provides fresh operating metrics, cash runway context, and a concrete regulatory timeline catalyst (FDA advisory committee in fall).
alphai scores every news story that mentions GRAL with an AI model for sentiment and relevance, and aggregates insider trades from GRAIL, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readGRAIL (GRAL) reported Q2 2026 results from its Galleri multi-cancer early detection test. The company cited PATHFINDER 2 (35,000 participants) and NHS-Galleri (140,000, three annual tests) presented at ASCO, with false positives under 0.5% and 61,000 tests sold in Q2. Q2 screening revenue was $42.6M, up 24% YoY; H1 revenue exceeded $80M. GRAIL completed a $110M financing with Samsung and is expanding internationally.
10 min readGRAIL said the FDA Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for Galleri, a multi-cancer early detection blood test. The submission cites PATHFINDER 2 (25,490 participants, one year) and NHS-Galleri (over 70,000). GRAIL says Galleri detects methylation patterns, with low false positives and accurate signal origin prediction.
2 min readGRAIL, Inc. (Nasdaq: GRAL) said the FDA’s Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for the Galleri multi-cancer early detection blood test. The filing is based on PATHFINDER 2 (25,490 participants, 1-year follow-up) and NHS-Galleri (70,000+ participants).
2 min readGRAIL, Inc. (GRAL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9912026q2earningspressre.htm EX-99.1 Document NEWS RELEASE Exhibit 99.1 GRAIL Reports Second Quarter 2026 Financial Results Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and
6 min readHagens Berman Sobol Shapiro LLP said a securities fraud class action was filed against GRAIL, Inc. (NASDAQ: GRAL), alleging misleading statements about the NHS-Galleri trial design and efficacy and selective promotion of results. The firm cites a Feb. 19, 2026 disclosure that the primary endpoint was not met and follow-up likely needed to be longer, after which GRAL shares fell 50.55% in a day. Lead plaintiff deadline is Aug. 4, 2026.
4 min readGrail (GRAL), a multi-cancer early detection test company backed early by Jeff Bezos and Bill Gates, was bought by Illumina in 2021 and spun off in 2024. Its Galleri test results from a UK NHS trial in February did not meet the primary Stage III-IV reduction endpoint, leading to a ~50% stock drop. The article cites a current price around $72 and discusses potential FDA approval and insurer coverage as key catalysts.
6 min readBleichmar Fonti & Auld LLP says a securities fraud class action was filed against GRAIL, Inc. (NASDAQ:GRAL) and executives after the company’s NHS-Galleri trial allegedly failed to support prior statements. The suit cites a ~50.55% stock drop (Feb. 19–20, 2026) and alleges violations of Exchange Act Sections 10(b) and 20(a). Investors have until Aug. 4, 2026 to seek lead-plaintiff status.
2 min readGRAIL, Inc. (GRAL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. gral-20260618 0001699031 FALSE 0001699031 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________________ CURRENT REPORT Pursuant to Section 13 or 15
2 min readGrail (GRAL) develops the Galleri multi-cancer early detection blood test, which it says screens for more than 50 cancer types. The article cites positive results from NHS Galleri 2 and Pathfinder 2 presented at the 2026 ASCO meeting, including >20% reductions in stage IV diagnoses for 12 cancers and higher detection of early-stage disease. Grail is seeking FDA approval (submitted Jan. 2026) and reported a $93.2 million net loss in Q1 2026.
6 min read
